Earnings Feed
Start Free
Sensei Biotherapeutics, Inc.·4

Jun 16, 4:21 PM ET

Hahn Stephen M. 4

Research Summary

AI-generated summary

Updated

Sensei Biotherapeutics Director Stephen Hahn Receives 25,000-Share Award

What Happened

  • Stephen M. Hahn, a director of Sensei Biotherapeutics (FTH), was granted 25,000 derivative shares (reported as an award) on June 12, 2026 at $0.00 (no cash paid).
  • The filing also reports conversion of a derivative security on June 15, 2026 that shows both acquisition and disposition of 44,763 common shares (price listed as N/A). These conversion entries likely relate to conversion/reclassification of securities rather than an open-market purchase or sale.

Key Details

  • Transaction dates: Grant/Award on 2026-06-12; Conversion of derivative security on 2026-06-15.
  • Grant: 25,000 shares @ $0.00 (derivative award). Reported value $0 in the filing.
  • Conversion: 44,763 shares acquired and 44,763 shares disposed on 2026-06-15 (price N/A). The filing records both acquisition and disposition for this conversion.
  • Shares owned after transaction: Not specified in the provided excerpt.
  • Footnotes of note:
    • F1: Each share of Series B Preferred is convertible into 1,000 shares of the issuer’s common stock and has no expiration date.
    • F2–F3: The Series B Preferred was issued in connection with a merger; outstanding HoldCo common was converted into Series B Preferred upon closing.
    • F4: The 25,000-share award is subject to vesting in 36 equal monthly installments (fully vested June 12, 2029), contingent on continued service.
  • Filing timeliness: No late filing flag indicated in the provided excerpt.

Context

  • The award is a derivative grant with a multi-year vesting schedule — not an immediate open-market purchase (a bullish signal when insiders buy stock outright).
  • The June 15 conversion entries appear to record internal conversions/reclassifications (e.g., Series B preferred into common following the merger) rather than a conventional sale to the market. The filing does not show a cash sale price or net proceeds.
  • For investors: awards and internal conversions provide information on compensation and capital structure changes but do not necessarily indicate director buying/selling sentiment.